VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update
Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern Time
Capital Markets Day Friday May 13 at 10:00 a.m. Eastern Time
AUSTIN, Texas, May 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday May 12, at 08.30 a.m. Eastern Time to discuss its financial and operating results for the first quarter 2022, in addition to providing a business update. Volition previously announced it will host a Capital Markets Day at the New York Stock Exchange on Friday May 13, details of said event can also be found below.
Event: VolitionRx Limited First Quarter 2022 Earnings and Business Update Conference Call
Date: Thursday, May 12, 2022
Time: 08:30 a.m. Eastern Time
U.S. & Canada Dial-in:1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Conference ID: 10167203
Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with Terig Hughes, Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on important events which have taken place in the first quarter of 2022 and upcoming milestones.
A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com. In addition, a telephone replay of the call will be available until May 25, 2022. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 10167203.
Event: VolitionRx Limited Capital Markets Day
Date: Friday, May 13, 2022
Time: 10:00 a.m. Eastern Time
In-person Venue: Siebert Hall, New York Stock Exchange
To attend in person, contact email@example.com
To attend virtually please register HERE
The event will be webcast and the presentations will be posted to Volition's website. A replay will be made available.
Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Volition's research and development activities are centered in Belgium, with an Innovation laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.
NucleosomicsTM is a trademark of Volition and its subsidiaries.
For more information about Volition, visit Volition's website (http://www.volition.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Louise Batchelor/Debra Daglish, Volition, firstname.lastname@example.org +44 (0)7557 774620
SOURCE VolitionRx Limited
Released May 6, 2022